← Eichor
Study identifier: NCT05339360 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

ZNN Bactiguard Antegrade Femoral Nails PMCF Study

Condition: Femur Fracture · Osteotomy  ·  Sponsor: Zimmer Biomet

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a multicenter, prospective, Post-market Clinical Follow-up (PMCF) Study on the ZNN Bactiguard Antegrade Femoral Nails. The objective of this study is to collect data confirming the safety, performance, and clinical benefit of the study device and instrumentation when used for the temporary internal fixation and stabilization of femoral fractures and osteotomies. This is a CE-marked device already available on the market and the aim of the study is to comply with the post-market surveillance requirements.

This description comes directly from the study's public registry record.

Talk to the study team

Gemma de Ramon Francàs  ·  +41 79 377 11 96  ·  gemma.deramonfrancas@zimmerbiomet.com

Lisa To  ·  +32 479 97 05 43  ·  lisa.to@zimmerbiomet.com

Always discuss trial participation with your own doctor first.

Locations (2)

Hospital Universitario Nuestra Señora de CandelariaSanta Cruz de Tenerife, Santa Cruz de Tenerife, SpainActive Not Recruiting
Manchester Royal InfirmaryManchester, Manchester, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05339360